Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban in Sickle Cell Disease
NCT02072668Phase 2Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Feb 2014
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of rivaroxaban in sickle cell anemia (SCA), Sickle Cell Beta-Zero Thalassemia (Sβ⁰-thalassemia), sponsored by University of North Carolina at Chapel Hill. Started Feb 2014; status: completed.
02
Drugs
rivaroxaban
03
Conditions
sickle cell anemia (SCA)Sickle Cell Beta-Zero Thalassemia (Sβ⁰-thalassemia)
Beyond the preview
Go deeper on NCT02072668.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02072668.